Committee Composition

Thomas J. Schall, Ph.D.

President, Chief Executive Officer and Director
One of the earliest investigators in the field of chemokine biology, Dr. Schall is the founder of our company and has served as our President, Chief Executive Officer and Director since November 1996. From December 1993 to November 1996, Dr. Schall worked at the DNAX Research Institute, a division of Schering-Plough Corporation, a pharmaceutical company. Prior to his work at the DNAX Research Institute, he worked as a scientist with Genentech, Inc., a pharmaceutical company. Dr. Schall participated in some of the earliest discoveries of chemokine system function and activities. Dr. Schall cloned one of the first chemokines to be discovered, and provided some of the earliest data for the existence of the previously unknown family of molecules which later came to be called the chemokines. Dr. Schall's laboratories have been responsible for the discovery or co-discovery of almost one-third of all known chemokine receptors. Dr. Schall received his B.S. in biology from Northern Illinois University and his Ph.D. in cancer biology from Stanford University.

Thomas A. Edwards

Former Partner, Latham & Watkins, LLP

Thomas Edwards has served on our board of directors since July 2015. Prior to his retirement from Latham & Watkins in 2014, Mr. Edwards supported dozens of biopharmaceutical companies in their general legal efforts, capital financings, acquisitions, partnerships and numerous other strategic business and legal initiatives. Mr. Edwards regularly represented companies and investment banking firms in public offerings, private placements, venture capital financings and corporate partnering arrangements. Mr. Edwards is a member of the American, California and San Diego Bar Associations. Mr. Edwards earned his bachelor's degree from Harvard College and his law degree from Harvard Law School.

Member of the Compensation Committee

Joseph M. Feczko M.D.

Former Senior Vice President and Chief Medical Officer, Pfizer Inc.

Dr. Feczko has served on our Board of Directors since April 2012. Until his retirement in May 2009, Dr. Feczko was Senior Vice President and Chief Medical Officer (CMO) of Pfizer Inc. and member of the Executive Leadership Team with global responsibilities for all aspects of the company's medical, regulatory and safety activities. Dr. Feczko served Pfizer in both New York and the United Kingdom since 1982, where he held positions of increasing responsibility in clinical research and regulatory affairs and safety, culminating in the role of Chief Medical Officer. Dr. Feczko is board-certified in Internal Medicine and Infectious Diseases. He has a B.Sc. degree from Loyola University Chicago, and an M.D. from the University of Illinois College of Medicine. Dr. Feczko also serves on the board of directors of the Keryx Biopharmaceuticals, Inc. and Cytheris, SA. Dr. Feczko also serves as chairman of the board of directors of Cardoz Pharmaceuticals AB (Stockholm, Sweden) and a member of the Supervisory Board of Amsterdam Molecular Therapeutics based in the Netherlands.

Member of the Compensation Committee

Roger C. Lucas Ph.D.

Vice Chairman, Techne Corporation

Dr. Lucas is a Director of Techne Corporation, a Series A investor in ChemoCentryx. A founding member of the staff at R&D Systems, now a division of Techne, Dr. Lucas guided that company's marked growth over 10 years, where he was a principal architect of R&D Systems' innovative deal making and acquisition of key competitors.

Techne Corporation, through its two R&D Systems subsidiaries, is the world's largest manufacturer and supplier of immunoregulatory molecules to the biomedical research community.

Dr. Lucas also sits on the Board of St. Croix Medical, Discovery Genomics, Zelo Technologies, Printware and Visual Circuits.

Member of the Compensation Committee

Henry A. McKinnell Jr., Ph.D.

Retired Chairman and Chief Executive Officer, Pfizer Inc.
Henry A. McKinnell has served on our board of directors since October 2016. Until his retirement in 2006, Dr. McKinnell was Chairman and Chief Executive Officer of Pfizer Inc., from 2001. After joining Pfizer in 1971 in Tokyo, Dr. McKinnell held positions of increasing responsibility around the world including president Asia, vice president strategic planning, chief financial officer and president and chief operating officer.
 
Dr. McKinnell serves as Chairman of Moody’s corporation. He also serves as a director of View Ray, Inc. and the Chairman Emeritus of the Connecticut Science Center. He has served as a Director of the Trilateral Commission and the Business Council, and Chairman of the Stanford University Graduate School of Business Advisory Council, Chairman Emeritus of the Business-Higher Education Forum, a Fellow of the New York Academy of Medicine, and a member of the Boards of Trustees of the New York City Public Library, the New York City Police Foundation and the Economic Club of New York. He served as the Chairman of the Accordia Global Health Foundation and also served as a Senior Advisor to Toyota Motor Corporation’s International Advisory Board and the Thomas H. Lee Private Equity Partnership. He is a Director of the Medal of Honor Foundation, the Royal Shakespeare Company of America and a life trustee of the Japan Society. He is the Chairman Emeritus of the Pharmaceutical Research and Manufacturers of America (Pharma), the Food and Drug Law Institute and the Medical Device Manufacturers Association. He has served as a director of more than 12 public companies over twenty years. Dr. McKinnell earned his bachelor’s degree in business from the University of British Columbia and his M.B.A. and Ph.D. degrees from Stanford University Graduate School of Business.
Member of the Compensation Committee

Geoffrey M. Parker

Chief Financial Officer, Anacor, Inc

Mr. Parker has served as a member of the ChemoCentryx Board of Directors since December 2009. Since September 2010, Mr. Parker has served as the Senior Vice President and Chief Financial Officer of Anacor after serving in a consulting capacity since December 2009. From July 2009 to July 2010, Mr. Parker served in a consulting capacity as the Chief Business Officer of InteKrin Therapeutics, a privately held biopharmaceutical company in Los Altos, California. From 1997 to April 2009, Mr. Parker was a Vice President, then Managing Director and finally Partner at the global investment banking and securities firm Goldman Sachs Group, Inc., leading their West Coast Healthcare Investment Banking practice during this time. Mr. Parker also served in various capacities with Goldman Sachs Group, Inc. from 1990 to 1995 and 1986 to 1988. From 1995 to 1997, Mr. Parker was Vice President at Feibusch & Co., a venture capital firm in Larkspur, California. Mr. Parker is currently a member of the board of directors of Genoptix, Inc., a specialized laboratory service provider and ChemoCentryx, Inc., a clinical stage privately held biopharmaceutical company. Mr. Parker received an A.B. from Dartmouth College in Engineering Sciences and Economics and an M.B.A. from Stanford University.

Member of the Compensation Committee

James L. Tyree

Former Executive Vice President, Abbott Laboratories

Mr. Tyree has served on our board of directors since June 2012. During the last fourteen years, Mr. Tyree has held numerous executive positions at Abbott Laboratories, including Corporate Vice President Pharmaceutical and Nutritional Products Group Business Development, Senior Vice President Global Nutrition and Executive Vice President Global Pharmaceuticals. He retired as President Abbott Biotechnology Ventures on March 31, 2012. Prior to joining Abbott, Mr. Tyree was the President of SUGEN, Inc., a biotechnology company focused on oncology. Earlier in his career, Mr. Tyree held management positions in Bristol-Myers Squibb, Pfizer and Abbott. Over his entire career, he was a four time expatriate living and working over six years in Latin America and seven years in Japan. Mr. Tyree is a member of the Advisory Board of the University of Chicago Graduate School of Business (BOOTH), a member of the Chicago Council on Global Affairs and co-chairman of the Global Health Policy Roundtable. Mr. Tyree also serves as a director for a number of privately held companies. Mr. Tyree earned Bachelor's Degrees in Psychology and Forensic Studies and a Master's Degree in Business Administration from Indiana University.

Chair of the Compensation Committee
  Audit Compensation Nominating and Governance
Thomas A. Edwards
Thomas A. Edwards
Former Partner, Latham & Watkins, LLP

Thomas Edwards has served on our board of directors since July 2015. Prior to his retirement from Latham & Watkins in 2014, Mr. Edwards supported dozens of biopharmaceutical companies in their general legal efforts, capital financings, acquisitions, partnerships and numerous other strategic business and legal initiatives. Mr. Edwards regularly represented companies and investment banking firms in public offerings, private placements, venture capital financings and corporate partnering arrangements. Mr. Edwards is a member of the American, California and San Diego Bar Associations. Mr. Edwards earned his bachelor's degree from Harvard College and his law degree from Harvard Law School.

Joseph M. Feczko, M.D.
Joseph M. Feczko, M.D.
Former Senior Vice President and Chief Medical Officer, Pfizer Inc.

Dr. Feczko has served on our Board of Directors since April 2012. Until his retirement in May 2009, Dr. Feczko was Senior Vice President and Chief Medical Officer (CMO) of Pfizer Inc. and member of the Executive Leadership Team with global responsibilities for all aspects of the company's medical, regulatory and safety activities. Dr. Feczko served Pfizer in both New York and the United Kingdom since 1982, where he held positions of increasing responsibility in clinical research and regulatory affairs and safety, culminating in the role of Chief Medical Officer. Dr. Feczko is board-certified in Internal Medicine and Infectious Diseases. He has a B.Sc. degree from Loyola University Chicago, and an M.D. from the University of Illinois College of Medicine. Dr. Feczko also serves on the board of directors of the Keryx Biopharmaceuticals, Inc. and Cytheris, SA. Dr. Feczko also serves as chairman of the board of directors of Cardoz Pharmaceuticals AB (Stockholm, Sweden) and a member of the Supervisory Board of Amsterdam Molecular Therapeutics based in the Netherlands.

Roger C. Lucas, Ph.D.
Roger C. Lucas, Ph.D.
Vice Chairman, Techne Corporation

Dr. Lucas is a Director of Techne Corporation, a Series A investor in ChemoCentryx. A founding member of the staff at R&D Systems, now a division of Techne, Dr. Lucas guided that company's marked growth over 10 years, where he was a principal architect of R&D Systems' innovative deal making and acquisition of key competitors.

Techne Corporation, through its two R&D Systems subsidiaries, is the world's largest manufacturer and supplier of immunoregulatory molecules to the biomedical research community.

Dr. Lucas also sits on the Board of St. Croix Medical, Discovery Genomics, Zelo Technologies, Printware and Visual Circuits.

Henry A. McKinnell, Jr., Ph.D.
Henry A. McKinnell, Jr., Ph.D.
Retired Chairman and Chief Executive Officer, Pfizer Inc.
Henry A. McKinnell has served on our board of directors since October 2016. Until his retirement in 2006, Dr. McKinnell was Chairman and Chief Executive Officer of Pfizer Inc., from 2001. After joining Pfizer in 1971 in Tokyo, Dr. McKinnell held positions of increasing responsibility around the world including president Asia, vice president strategic planning, chief financial officer and president and chief operating officer.
 
Dr. McKinnell serves as Chairman of Moody’s corporation. He also serves as a director of View Ray, Inc. and the Chairman Emeritus of the Connecticut Science Center. He has served as a Director of the Trilateral Commission and the Business Council, and Chairman of the Stanford University Graduate School of Business Advisory Council, Chairman Emeritus of the Business-Higher Education Forum, a Fellow of the New York Academy of Medicine, and a member of the Boards of Trustees of the New York City Public Library, the New York City Police Foundation and the Economic Club of New York. He served as the Chairman of the Accordia Global Health Foundation and also served as a Senior Advisor to Toyota Motor Corporation’s International Advisory Board and the Thomas H. Lee Private Equity Partnership. He is a Director of the Medal of Honor Foundation, the Royal Shakespeare Company of America and a life trustee of the Japan Society. He is the Chairman Emeritus of the Pharmaceutical Research and Manufacturers of America (Pharma), the Food and Drug Law Institute and the Medical Device Manufacturers Association. He has served as a director of more than 12 public companies over twenty years. Dr. McKinnell earned his bachelor’s degree in business from the University of British Columbia and his M.B.A. and Ph.D. degrees from Stanford University Graduate School of Business.
Geoffrey M. Parker
Geoffrey M. Parker
Chief Financial Officer, Anacor, Inc

Mr. Parker has served as a member of the ChemoCentryx Board of Directors since December 2009. Since September 2010, Mr. Parker has served as the Senior Vice President and Chief Financial Officer of Anacor after serving in a consulting capacity since December 2009. From July 2009 to July 2010, Mr. Parker served in a consulting capacity as the Chief Business Officer of InteKrin Therapeutics, a privately held biopharmaceutical company in Los Altos, California. From 1997 to April 2009, Mr. Parker was a Vice President, then Managing Director and finally Partner at the global investment banking and securities firm Goldman Sachs Group, Inc., leading their West Coast Healthcare Investment Banking practice during this time. Mr. Parker also served in various capacities with Goldman Sachs Group, Inc. from 1990 to 1995 and 1986 to 1988. From 1995 to 1997, Mr. Parker was Vice President at Feibusch & Co., a venture capital firm in Larkspur, California. Mr. Parker is currently a member of the board of directors of Genoptix, Inc., a specialized laboratory service provider and ChemoCentryx, Inc., a clinical stage privately held biopharmaceutical company. Mr. Parker received an A.B. from Dartmouth College in Engineering Sciences and Economics and an M.B.A. from Stanford University.

James L. Tyree
James L. Tyree
Former Executive Vice President, Abbott Laboratories

Mr. Tyree has served on our board of directors since June 2012. During the last fourteen years, Mr. Tyree has held numerous executive positions at Abbott Laboratories, including Corporate Vice President Pharmaceutical and Nutritional Products Group Business Development, Senior Vice President Global Nutrition and Executive Vice President Global Pharmaceuticals. He retired as President Abbott Biotechnology Ventures on March 31, 2012. Prior to joining Abbott, Mr. Tyree was the President of SUGEN, Inc., a biotechnology company focused on oncology. Earlier in his career, Mr. Tyree held management positions in Bristol-Myers Squibb, Pfizer and Abbott. Over his entire career, he was a four time expatriate living and working over six years in Latin America and seven years in Japan. Mr. Tyree is a member of the Advisory Board of the University of Chicago Graduate School of Business (BOOTH), a member of the Chicago Council on Global Affairs and co-chairman of the Global Health Policy Roundtable. Mr. Tyree also serves as a director for a number of privately held companies. Mr. Tyree earned Bachelor's Degrees in Psychology and Forensic Studies and a Master's Degree in Business Administration from Indiana University.

= Chair = Member